ERBB2 and breast carcinoma: In conclusion, based on the small differences reported in the positive studies and the large number of studies that haven't shown differences in prognosis, HER2-low does not appear to be a biological distinct breast cancer subtype; but rather, low levels of HER2-expression could be used as a predictive marker of response to therapies, as seen on DESTINY-Breast04 [12].